cordycepin has been researched along with Pancreatic Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, H; Cheng, J; Du, J; Fu, J; He, T; Zhang, L; Zhang, W | 1 |
| Ding, K; DU, ZY; Jin, C; Li, XY; Liao, WF; Tang, QJ; Tao, H | 1 |
2 other study(ies) available for cordycepin and Pancreatic Neoplasms
| Article | Year |
|---|---|
Effect of DPP4/CD26 expression on SARS‑CoV‑2 susceptibility, immune response, adenosine (derivatives m
Topics: Adenocarcinoma; Adenosine; Carcinoma, Hepatocellular; COVID-19; Dipeptidyl Peptidase 4; Female; Humans; Immunity; Liver Neoplasms; Male; Melanoma; Melanoma, Cutaneous Malignant; Pancreatic Neoplasms; Pandemics; Prospective Studies; SARS-CoV-2; Skin Neoplasms | 2023 |
Cordycepin inhibits pancreatic cancer cell growth in vitro and in vivo via targeting FGFR2 and blocking ERK signaling.
Topics: Animals; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cordyceps; Deoxyadenosines; Drugs, Chinese Herbal; Female; Humans; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Pancreatic Neoplasms; Receptor, Fibroblast Growth Factor, Type 2 | 2020 |